Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Sugimoto, Keiki ^a,b   Hayakawa, Fumihiko ^a   Shimada, Satoko ^c   Morishita, Takanobu ^a   Shimada, Kazuyuki ^a   Katakai, Tomoya ^d   Tomita, Akihiro ^a   Kiyoi, Hitoshi ^a   Naoe, Tomoki ^a,e  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLUTATHIONE; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; PYRVINIUM EMBONATE; REACTIVE OXYGEN METABOLITE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; DEFICIENCY; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; KNOCKOUT MOUSE; LYMPHOMA; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; OXIDATIVE STRESS; PATHOLOGY; PROCEDURES; SCID MOUSE; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; DRUG DISCOVERY; GLUTATHIONE; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LYMPHOMA; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; OXIDATIVE STRESS; PYRVINIUM COMPOUNDS; REACTIVE OXYGEN SPECIES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939433151     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13054     Document Type: Article

References (33)

1. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature medicine 2, 561-566 (1996).
2. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England journal of medicine 363, 1693-1703 (2010).
3. Kindler, T., Lipka, D. B. & Fischer, T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116, 5089-5102 (2010).
4. Koppikar, P. et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489, 155-159 (2012).
5. Kim, S. M. et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in nonsmall cell lung cancer with T790M resistance mutation. Molecular cancer therapeutics 11, 2254-2264 (2012).
6. Kopetz, S., Lemos, R. & Powis, G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clinical cancer research: an official journal of the American Association for Cancer Research 18, 5160-5162 (2012).
7. Meads, M. B., Gatenby, R. A. & Dalton, W. S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nature reviews. Cancer 9, 665-674 (2009).
8. Sharma, S. V., Haber, D. A. & Settleman, J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature reviews. Cancer 10, 241-253 (2010).
9. Kridel, R., Sehn, L. H. & Gascoyne, R. D. Pathogenesis of follicular lymphoma. The Journal of clinical investigation 122, 3424-3431 (2012).
10. Gonzalez, S. F. et al. Trafficking of B cell antigen in lymph nodes. Annual review of immunology 29, 215-233 (2011).
11. Rehm, A. et al. Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood 118, 1020-1033 (2011).
12. Ito, M. et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100, 3175-3182 (2002).
13. Katakai, T., Hara, T., Sugai, M., Gonda, H. & Shimizu, A. Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. The Journal of experimental medicine 200, 783-795 (2004).
14. Most, H. Treatment of common parasitic infections of man encountered in the United States. I. The New England journal of medicine 287, 495-498 (1972).
15. Smith, T. C., Kinkel, A. W., Gryczko, C. M. & Goulet, J. R. Absorption of pyrvinium pamoate. Clinical pharmacology and therapeutics 19, 802-806 (1976).
16. Jones, J. O. et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 106, 7233-7238 (2009).
17. Ishii, I., Harada, Y. & Kasahara, T. Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration. Frontiers in oncology 2, 137 (2012).
18. Thorne, C. A. et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nature chemical biology 6, 829-836 (2010).
19. Zhang, W. et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nature cell biology 14, 276-286 (2012).
20. DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature medicine 17, 1514-1520 (2011).
21. Zhao, X. et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro-oncology 14, 574-583 (2012).
22. Morton, C. L. & Houghton, P. J. Establishment of human tumor xenografts in immunodeficient mice. Nature protocols 2, 247-250 (2007).
23. Reyal, F. et al. Molecular profiling of patient-derived breast cancer xenografts. Breast cancer research: BCR 14, R11 (2012).
24. Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Molecular cancer therapeutics 10, 1311-1316 (2011).
25. Neale, G. et al. Molecular characterization of the pediatric preclinical testing panel. Clinical cancer research : an official journal of the American Association for Cancer Research 14, 4572-4583 (2008).
26. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature medicine 3, 730-737 (1997).
27. Tanizaki, R. et al. Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD/SCID/IL-2Rgammac-/-mice. Cancer science 101, 631-638 (2010).
28. Daniel, V. C. et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer research 69, 3364-3373 (2009).
29. Rolff, J., Dorn, C., Merk, J. & Fichtner, I. Response of patient-derived non-small cell lung cancer xenografts to classical and targeted therapies is not related to multidrug resistance markers. Journal of oncology 2009, 814140 (2009).
30. Morelli, M. P. et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30, e45-48 (2012).
31. Amini, R. M. et al. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leukemia & lymphoma 43, 2179-2189 (2002).
32. Kurahashi, S. et al. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. Oncogene 30, 1822-1830 (2011).
33. Toyooka, T. & Imai, K. Isolation and characterization of cysteine-containing regions of proteins using 4-(aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole and high-performance liquid chromatography. Analytical chemistry 57, 1931-1937 (1985).